



HEPATITIS B

GLOBAL CLINICAL TRIAL LANDSCAPE (2025)

#DYK
Did you know?

Hepatitis B is a **highly infectious liver disease** that can lead to **chronic infection, cirrhosis, and cancer**



2022

254M

CHRONIC HEPATITIS B CASES

1.1M

GLOBAL DEATHS

The African region carries a substantial Hepatitis B burden, with **South Africa among the most affected countries**

In the **Asia-Pacific, China and India report the highest prevalence**, making the region a key focus for intervention

In **Europe & the Americas**, countries like Germany and the U.S. continue to **face challenges in managing Hepatitis B cases**



Trials advance treatment through **RNAi, gene therapies, therapeutic vaccines, and epigenetic modifiers** some of which are aimed at achieving complete cure



The U.S. and China led Hepatitis B **venture funding**, with significant contributions from the **UK, Singapore, France, and Taiwan**

HEPATITIS B TRIAL CONTRIBUTIONS

Countries like **Mainland China, Hong Kong, South Korea, Taiwan, and the United States**, emerged as top locations for conducting trials

Hepatitis B trials **utilize biomarkers for disease management**, with emerging markers like HBV RNA and HBcrAg enhancing diagnostics and treatment

